Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.

OBJECTIVE: We previously showed that exenatide (EXE) enhanced insulin secretion after 1 year of treatment, relative to insulin glargine (GLAR), with a similar glucose-lowering action. These effects were not sustained after a 4-week off-drug period. This article reports the results after additional 2... View More